Eric Dobmeier is President, CEO of CHINOOK THERAPEUTICS, INC.. Currently has a direct ownership of 0 shares of KDNY, which is worth approximately $0. The most recent transaction as insider was on Aug 11, 2023, when has been sold 301,138 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

ERIC DOBMEIER Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 11 2023
SELL
Sale (or disposition) back to the issuer
-
301,138 Reduced 100.0%
0 Common Stock
Apr 24 2023
SELL
Open market or private sale
$513,603 $21.58 p/Share
23,800 Reduced 7.3%
302,338 Common Stock
Apr 24 2023
BUY
Open market or private sale
$26,712 $22.26 p/Share
1,200 Added 0.4%
301,138 Common Stock
Apr 24 2023
BUY
Exercise of conversion of derivative security
$10,500 $0.42 p/Share
25,000 Added 7.12%
326,138 Common Stock
Feb 10 2023
SELL
Open market or private sale
$192,303 $23.75 p/Share
8,097 Reduced 2.62%
301,138 Common Stock
Feb 10 2023
BUY
Exercise of conversion of derivative security
-
20,248 Added 6.15%
309,235 Common Stock
Jan 31 2023
SELL
Open market or private sale
$189,739 $24.68 p/Share
7,688 Reduced 2.59%
288,987 Common Stock
Jan 31 2023
BUY
Exercise of conversion of derivative security
-
24,999 Added 7.77%
296,675 Common Stock
Jan 30 2023
SELL
Open market or private sale
$613,500 $24.54 p/Share
25,000 Reduced 8.43%
271,676 Common Stock
Jan 30 2023
BUY
Exercise of conversion of derivative security
$10,500 $0.42 p/Share
25,000 Added 7.77%
296,676 Common Stock
Dec 14 2022
BUY
Exercise of conversion of derivative security
$10,500 $0.35 p/Share
30,000 Added 9.94%
271,676 Common Stock
Dec 01 2022
SELL
Open market or private sale
$669,300 $22.31 p/Share
30,000 Reduced 11.04%
241,676 Common Stock
Dec 01 2022
SELL
Bona fide gift
-
25,000 Reduced 10.56%
211,676 Common Stock
Dec 01 2022
BUY
Exercise of conversion of derivative security
$25,200 $0.42 p/Share
60,000 Added 18.09%
271,676 Common Stock
Oct 06 2022
BUY
Exercise of conversion of derivative security
-
30,796 Added 11.51%
236,676 Common Stock
May 25 2022
BUY
Open market or private purchase
$65,150 $13.03 p/Share
5,000 Added 2.37%
205,880 Common Stock
Feb 10 2022
BUY
Exercise of conversion of derivative security
-
20,247 Added 9.16%
200,880 Common Stock
Dec 23 2021
BUY
Exercise of conversion of derivative security
$14,000 $0.35 p/Share
40,000 Added 18.13%
180,633 Common Stock
Oct 06 2021
BUY
Exercise of conversion of derivative security
-
30,796 Added 17.96%
140,633 Common Stock
Sep 20 2021
BUY
Open market or private purchase
$24,000 $12.0 p/Share
2,000 Added 1.79%
109,837 Common Stock
Aug 19 2021
BUY
Open market or private purchase
$36,000 $12.0 p/Share
3,000 Added 2.71%
107,837 Common Stock
Aug 18 2021
BUY
Open market or private purchase
$82,180 $11.74 p/Share
7,000 Added 6.26%
104,837 Common Stock
Jun 14 2021
BUY
Exercise of conversion of derivative security
$7,000 $0.35 p/Share
20,000 Added 16.97%
97,837 Common Stock
May 14 2021
BUY
Open market or private purchase
$14,440 $14.44 p/Share
1,000 Added 1.27%
77,837 Common Stock
Dec 21 2020
BUY
Exercise of conversion of derivative security
$7,000 $0.35 p/Share
20,000 Added 20.65%
76,837 Common Stock

Also insider at

ADPT
Adaptive Biotechnologies Corp Healthcare
ATRA
Atara Biotherapeutics, Inc. Healthcare
GPCR
Structure Therapeutics Inc.
JANX
Janux Therapeutics, Inc. Healthcare
ED

Eric Dobmeier

President, CEO
Seattle, WA

Track Institutional and Insider Activities on KDNY

Follow CHINOOK THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KDNY shares.

Notify only if

Insider Trading

Get notified when an Chinook Therapeutics, Inc. insider buys or sells KDNY shares.

Notify only if

News

Receive news related to CHINOOK THERAPEUTICS, INC.

Track Activities on KDNY